{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021888","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.824673+00:00","generated_at":"2026-06-22T09:54:37.283218+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences Q3 net loss widens to $12.5M; CFO van den Boom to step down, Fuhrman appointed","bullets":["Net loss of $12.5M in Q3 2022 vs $6.6M a year ago; cash and equivalents $263.2M.","R&D expenses $10.9M (up from $5.5M); G&A expenses $2.7M (up from $1.2M).","CFO Esther van den Boom resigns effective Dec 31, 2022; will provide transitional consulting services.","Alan Fuhrman appointed CFO effective Jan 1, 2023; base salary $440k, target bonus 40%, equity grants.","SURF301 study ongoing; IND for TYRA-200 expected by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021888","json":"https://secwatch.observer/filing/0000950170-22-021888.json","markdown":"https://secwatch.observer/filing/0000950170-22-021888.md","text":"https://secwatch.observer/filing/0000950170-22-021888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/tyra-20221028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:54:37.283218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd6c1b0028b68937293924667fd5d812465b9a11","claim":"Tyra Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income Third quarter 2022 net loss was $12.5 million.","evidence_excerpt":"On November 3, 2022, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"Third quarter 2022 net loss was $12.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2b5de6fcac","claim":"Esther van den Boom departed as Chief Financial Officer at Tyra Biosciences, Inc..","evidence_excerpt":"On October 28, 2022, Esther van den Boom, the Chief Financial Officer of Tyra Biosciences, Inc. (the “Company”), informed the Company of her intent to resign as the Company’s Chief Financial Officer, effective December 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"8b39acc283","claim":"Alan Fuhrman was appointed as Chief Financial Officer at Tyra Biosciences, Inc..","evidence_excerpt":"On November 1, 2022, the Board of Directors of the Company (the “Board”) appointed Alan Fuhrman to replace Ms. van den Boom as the Company’s Chief Financial Officer, effective January 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}